Virax Biolabs Group Limited · NASDAQ:VRAX
Virax Biolabs — Investor Presentation (November 2026)
15 slides from Virax Biolabs's investor presentation, November 2026
Slide 1: Developing blood-based immune diagnostics
Developing blood-based immune diagnostics Initial focus: post-acute infection syndromes Investor Presentation | Q4 2026 | NASDAQ: VRAX
Slide 2: Forward-Looking Statements
NASDAQ: VRAX IMPORTANT INVESTOR INFORMATION Forward-Looking Statements. This presentation contains forward-looking statements. We base these forward-looking Although we believe the expectations reflected in such forward-looking statements are statements on our expectations and projections about futu
Slide 3: Building a Clinical Diagnostics Business Around Functional Immune Profiling
NASDAQ: VRAX VIRAX TODAY | THE INVESTMENT CASE Building a Clinical Diagnostics Business Around Functional Immune Profiling. ViraxImmune is the development platform for clinical testing. ImmuneSelect provides a separate, commercially available research-use-only (RUO) product portfolio. 88% | 92% 2027
Slide 4: Millions Affected. A Significant Diagnostic Gap.
NASDAQ: VRAX THE CLINICAL OPPORTUNITY | POST-ACUTE INFECTION SYNDROMES (PAIS) Millions Affected. A Significant Diagnostic Gap. Long COVID and myalgic encephalomyelitis/chronic 21.3M fatigue syndrome (ME/CFS) U.S. adults estimated to have involve persistent, overlapping ever experienced Long COVID sy
Slide 5: Translating T cell Responses into Objective Immune Insights
NASDAQ: VRAX VIRAXIMMUNE | FUNCTIONAL T CELL PROFILING Translating T cell Responses into A functional cellular readout designed to characterise antigen-specific T cell responses Objective Immune Insights. through cytokine secretion. 01 02 03 04 05 Blood sample Cell isolation Antigen stimulation Vira
Slide 6: Objective Immune Data to Support Clinical Assessment
NASDAQ: VRAX VIRAXIMMUNE PROPOSED CLINICAL ROLE Objective Immune Data to Support Clinical Assessment. PATIENT SETTING PROPOSED TEST CONTRIBUTION PROPOSED CLINICAL VALUE Persistent symptoms Objective immune- Assessment and patient after infection dysfunction profiling stratification Patients undergoi
Slide 7: Early Pilot Data Support Further Clinical Development
NASDAQ: VRAX EARLY CLINICAL EVIDENCE | REPORTED MAY 2026 Early Pilot Data Support Further Clinical Development Virax reported measurable separation between PAIS patient samples and healthy controls in an exploratory pilot dataset. 88% 92% SPECIFICITY POSITIVE PREDICTIVE VALUE (PPV) Reported pilot re
Slide 8: Clinical Studies and Research Collaborators
NASDAQ: VRAX CLINICAL DEVELOPMENT Clinical Studies and Research Collaborators. CLINICAL PROGRAMME REPORTED POSITION DEVELOPMENT CONTRIBUTION 160 recruited, Nov 2025. UK patient cohort Explore T cell profiles across PAIS cohorts and healthy Results timing revised beyond VRX-002 [A4] controls. Analysi
Slide 9: A proposed Virax-owned U.S. testing business using hosted laboratory facilities
NASDAQ: VRAX U.S. COMMERCIAL STRATEGY A proposed Virax-owned U.S. testing Physician 01 order business using hosted laboratory facilities Proposed laboratory-developed test (LDT) service using hosted facilities, with Virax 02 Local sample retaining assay and testing revenue rights. Designed to limit
Slide 10: Research Products with Expanding International Distribution
NASDAQ: VRAX IMMUNESELECT RESEARCH PRODUCTS Research Products with Expanding Research reagents and custom services: peptide pools, ELISpot/FluoroSpot reagents and custom International Distribution. assay services for research laboratories, biotech and CRO customers. 01 UK & Continental Europe Cambri
Slide 11: Restructured Operating Model Focused on Validation and U.S. Launch Preparation
NASDAQ: VRAX FINANCIAL POSITION | 30 SEPTEMBER 2026 | UNAUDITED Restructured Operating Model Focused on Validation and U.S. Launch Preparation. $5.12M $7.40M $0.99M $6.41M CASH TOTAL ASSETS TOTAL LIABILITIES CONSOLIDATED NET ASSETS ~$2.4M LOWER PLANNED FIXED COSTS The 2026 restructuring programme ta
Slide 12: Milestones that Advance the Investment Case
NASDAQ: VRAX DEVELOPMENT AND COMMERCIAL PRIORITIES Milestones that Advance Management priorities over the next 6–12 months. 2027 TARGET Initial U.S. LDT launch through the proposed the Investment Case. hosted laboratory model. 2028 TARGET Potential FDA De Novo submission. CLINICAL EVIDENCE U.S. LABO
Slide 13: Building an Immune Diagnostics Business With a Focused Path to Market
NASDAQ: VRAX THE VIRAX INVESTMENT PROPOSITION Building an Immune Diagnostics Business With a Focused Path to Market. 01 02 03 ViraxImmune U.S. Testing Business ImmuneSelect Functional immune profiling initially focused Proposed Virax-owned testing business Research products with international on PAI
Slide 14: Appendix A: Clinical Evidence and Development References
NASDAQ: VRAX APPENDIX A | REFERENCES Clinical Evidence and Development. A1 Shah et al. JAMA Network Open. 2026;9(3):e260374. Estimated 21.3M U.S. adults who had ever experienced Long COVID, based on the 2024 NHIS. CDC | ME/CFS Basics Estimated annual U.S. economic burden of ME/CFS: $18–$51bn. Access
Slide 15: Appendix B: Commercial and Financial Sources
NASDAQ: VRAX APPENDIX B | REFERENCES Commercial and Financial Sources. B1 Research catalogue and distributors ELISpot kits, peptide pools and research services. Accessed 3 November 2026 UK, Europe, North America and Asia channels. B2 Fosun supply framework Six ASEAN markets under a supply framework.
Virax Biolabs Group — Investor Presentation (November 2026) on 6ix